Trastuzumab
- Generic Name
- Trastuzumab
- Brand Names
- Herceptin, Herceptin Hylecta, Herzuma, Kanjinti, Ontruzant, Perjeta-Herceptin, Phesgo, Trazimera, Herwenda, Ogivri, Zercepac, Tuznue
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 180288-69-1
- Unique Ingredient Identifier
- P188ANX8CK
- Background
Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal growth factor receptor (HER)-2+ metastatic bre...
- Indication
For the adjuvant treatment of HER2-overexpressing breast cancer, trastuzumab is indicated in several clinical settings: as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel; as part of a treatment regimen with docetaxel and carboplatin; or as monotherapy following multi-modality anthracycline-based th...
- Associated Conditions
- Breast Cancer, Inflammatory Breast Cancer (IBC), Locally Advanced Breast Cancer (LABC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Adenocarcinoma of the Stomach, Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Stage I Breast Cancer
- Associated Therapies
- -
XRP9881 in Combination With Trastuzumab in Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2006-10-11
- Last Posted Date
- 2011-04-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 51
- Registration Number
- NCT00386685
- Locations
- 🇨🇭
Sanofi-Aventis Administrative Office, Geneva, Switzerland
Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.
- Conditions
- Interventions
- First Posted Date
- 2006-08-23
- Last Posted Date
- 2020-09-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 31
- Registration Number
- NCT00367471
- Locations
- 🇺🇸
Novartis Investigative Site, Greensboro, North Carolina, United States
Safety Study of Combined Immunotherapy With Trastuzumab and Cetuximab in Patients With Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2006-08-22
- Last Posted Date
- 2010-09-28
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 32
- Registration Number
- NCT00367250
- Locations
- 🇦🇹
Dept of Internal Medicine, Vienna, Austria
Pilot Study of Docetaxel & Bevacizumab +/- Trastuzumab in First-Line Treatment of Patients With Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-08-15
- Last Posted Date
- 2012-08-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 73
- Registration Number
- NCT00364611
- Locations
- 🇺🇸
Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States
Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-04-25
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT00317720
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Randomized Neoadjuvant Study of Epirubicin and Docetaxel With/Without Capecitabine in Early Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-04-03
- Last Posted Date
- 2011-12-30
- Lead Sponsor
- Austrian Breast & Colorectal Cancer Study Group
- Target Recruit Count
- 536
- Registration Number
- NCT00309556
- Locations
- 🇦🇹
Hospital BHB St. Veit/Glan, Surgery, St. Veit a. d. Glan, Carinthia, Austria
🇦🇹State Hospital Klagenfurt, Klagenfurt, Carinthia, Austria
🇦🇹Hospital Guessing, Guessing, Burgenland, Austria
Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-03-15
- Last Posted Date
- 2016-11-03
- Lead Sponsor
- US Oncology Research
- Target Recruit Count
- 136
- Registration Number
- NCT00303108
- Locations
- 🇺🇸
Missouri Cancer Associates, Columbia, Missouri, United States
🇺🇸Texas Cancer Center, Arlington, Texas, United States
🇺🇸Hematology Oncology Associates of IL, Chicago, Illinois, United States
Trastuzumab and Oxaliplatin in Patients With Metastatic Breast Cancer
- First Posted Date
- 2006-02-28
- Last Posted Date
- 2021-10-28
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 25
- Registration Number
- NCT00297596
- Locations
- 🇺🇸
Graves-Gilbert Clinic, Bowling Green, Kentucky, United States
🇺🇸Oncology Hematology Care, Cincinnati, Ohio, United States
🇺🇸Chattanooga Oncology and Hematology Associates, Chattanooga, Tennessee, United States
Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2neu) Over-Expressing Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-01-31
- Last Posted Date
- 2013-08-09
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 32
- Registration Number
- NCT00284180
- Locations
- 🇺🇸
Associates in Hematology Oncology, Chattanooga, Tennessee, United States
🇺🇸Northeast Alabama Regional Medical Center, Anniston, Alabama, United States
🇺🇸Tennessee Oncology, Nashville, Tennessee, United States
ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib
- Conditions
- Interventions
- First Posted Date
- 2006-01-09
- Last Posted Date
- 2023-04-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 63
- Registration Number
- NCT00272987
- Locations
- 🇧🇪
Novartis Investigative Site, Liege, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.